Strong foundation for future growth and earnings
Despite the financial crisis and an economic slowdown, Bavarian Nordic recorded a positive development in 2008, and has laid a strong foundation for further value creation in 2009 and the years ahead. The expected positive development is based on the following elements:
- Two vaccines moving into Phase III trials - Strong financial position - Profitable ongoing development and procurement contracts with a value of more than DKK 3.5 billion - Expectations to the US government's exercise of the contract option for additional development and procurement, worth more than DKK 6 billion - Ongoing contracts with countries outside USA - Partnership with the NCI, a world leading cancer research organisation - Strong patent portfolio - Pipeline with promising results - Future licensing agreement for PROSTVAC(TM) - The world's only manufacturing facility dedicated to the commercial-scale production of MVA based vaccines Important events after the balance sheet date IMVAMUNE(R) - end-of-Phase II meeting held with the FDA
After concluding the Phase II development of IMVAMUNE(R), Bavarian Nordic held an end-of-Phase-II meeting with the US health authorities (FDA) in the beginning of 2009 in order to discuss the Phase III study design. The meeting was a success and there was an open and highly constructive discussion with the FDA. Based on the meeting, Phase III studies are expected to be initiated in 2010.
The outcome of the meeting has no impact on the delivery of vaccines to
the Strategic National Stockpile (SNS) under the RFP-
|SOURCE Bavarian Nordic A/S|
Copyright©2009 PR Newswire.
All rights reserved